Barcelona Liver Bioservices Presents New Data on the Antifibrotic Potential of Liraglutide at AEEH


Madrid, 19 February 2026

Barcelona Liver Bioservices is proud to announce the oral presentation of its latest research, titled “Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling”, at the annual congress of the Asociación Española para el Estudio del Hígado (AEEH).

The study highlights the potential of liraglutide to exert antifibrotic effects through the deactivation of hepatic stellate cells (HSCs) and the remodeling of the extracellular matrix (ECM), two central mechanisms in the progression of liver fibrosis. These findings provide further evidence supporting the therapeutic relevance of targeting fibrogenic pathways in chronic liver disease.

A key aspect of this work is the use of a cutting-edge experimental platform based on microfluidic human precision-cut liver slices (PCLS) maintained in long-term culture conditions. This advanced methodology enables the preservation of the complex multicellular architecture and functionality of human cirrhotic liver tissue, offering a highly translational model for drug testing and mechanistic studies.

Importantly, this human PCLS long-term culture platform is now fully integrated into the Barcelona Liver Bioservices portfolio, reinforcing the company’s commitment to delivering state-of-the-art preclinical solutions to accelerate liver disease research and therapeutic development.

This presentation at AEEH underscores Barcelona Liver Bioservices’ position at the forefront of innovation in human-based liver models and its dedication to bridging the gap between experimental research and clinical application.

About Barcelona Liver Bioservices (BLB)

Barcelona Liver Bioservices is a specialized CRO focused on translational research in liver diseases. With cutting-edge in vivoex vivo, and omics-based platforms, BLB provides customized preclinical solutions to support drug discovery and development in hepatology.

🔗 To learn more about our services or explore potential collaborations, visit: https://liver.barcelona/

More News

Barcelona Liver Bioservices (BLB) starts operations

Barcelona Liver Bioservices (BLB), a spin-off of IDIBAPS, has been created for the design and development of pre-clinical studies in the fields of hepatology and hepatotoxicity. The co-founders are Jordi Gracia-Sancho, Jaume Bosch and Joan Carles Garcia-Pagan from IDIBAPS and Rosa Villa from CSIC.

Read More »